



behavioural specificity is uncertain,
however.Recently, symptomprovocation
studies have become controversial,
particularly inthe USA.
Aims To assess the specificityof acute
tryptophan depletion.To investigate
systematically the subjective experiences




tryptophan depletion in a double-blind,





Results Acute tryptophan depletion
induced a specific depressive response.
The effectsweremore pronounced in
females than inmales.Participantswere
quite satisfiedwiththe informed consent
procedure.Theyhadunderstood thatthis
was a fundamentalresearch project and
personalbenefitswerenotexpected.
However, someparticipants still found it a
positive experience.
Conclusions Acute tryptophan
depletion is a suitablemodel of
vulnerability to depression, fromboth a
scientific and an ethicalperspective.
Declaration of interest None.
Fundingdetailed in Acknowledgements.
Acute tryptophan depletion induces
transient symptoms in 50–60% of those
with remitted depression treated with a
serotonergic antidepressant (Booij et al,
2003). Evidence suggests that it causes a
return of symptoms that were present be-
fore treatment (Delgado et al, 1990), but
others argue that it mainly induces physical
symptoms (Lam & Yatham, 2003). Studies
have almost exclusively relied on the
Hamilton Rating Scale for Depression
(HRSD), which includes many somatic
items (Hamilton, 1960). Hence, the behav-
ioural specificity of acute tryptophan deple-
tion is still uncertain. Furthermore,
symptom provocation studies are now con-
troversial. For instance, front-page articles
in The Boston Globe (Whitaker & Kong,
1998) accused researchers of abusing pa-
tients for financial profit or professional
advancement. No lasting or serious side-
effects have been reported for acute trypto-
phan depletion, suggesting that the
procedure is safe. However, the views of
participants have not been investigated.
The aims of the present study were to
investigate the behavioural specificity of
acute tryptophan depletion and to collect




Eligible participants for the acute trypto-
phan depletion trial were out-patients of a
mood disorders clinic. Inclusion criteria
were: age between 18 and 65 years; on-
going treatment with a selective serotonin
reuptake inhibitor (SSRI) or serotonin–
noradrenaline reuptake inhibitor (SNRI)
for at least 4 weeks; meeting DSM–IV
criteria for depression in remission
(American Psychiatric Association, 1994);
and an HRSD (17-item version) score lower
than 15. Exclusion criteria were: major
physical illness; substance misuse within
the past 3 months; psychosis (lifetime);
lactation; and pregnancy. Diagnoses were
clarified with the Structured Clinical Inter-
view for DSM–IV (SCID; First et al,
1995). After a complete oral and written
description of the study, written informed
consent was obtained. Twenty-three par-
ticipants were enrolled in the trial, two of
whom subsequently withdrew.
After the tryptophan challenge, all 23
participants, together with a further 18
(10 females) who had participated in
another acute tryptophan depletion project,
were asked to complete a questionnaire
about their experiences during the study.
Participants in the other project also had
remitted depression and the design, pro-
cedure and inclusion criteria of that project
were identical to the present study.
Design
The study had a randomised double-blind
crossover design with two depletion
sessions, separated by at least 4 days. The
hospital pharmacist was responsible for
the randomisation.
Amino acid mixtures
At each depletion session, patients received
in randomised order either a 100 g or a 25 g
amino acid mixture. The composition of
the 100 g mixture (aimed at reducing tryp-
tophan levels by 90%) was as follows:
5.5 g L-alanine, 3.2 g L-histidine, 13.5 g L-
leucine, 12.2 g L-proline, 6.9 g L-tyrosine,
4.9 g L-arginine, 5.7 g L-phenylalanine,
6.9 g L-threonine, 6.9 g L-serine, 8.9 g
L-valine, 2.7 g L-cysteine, 8.0 g L-isoleucine,
3.0 g L-methionine, 11.0 g L-lysine HCL
and 3.2 g glycine. The 25 g mixture (aimed
at 50% reduction) consisted of the same
amino acids but in one-quarter the amount
(Krahn et al, 1996). Amino acids were
mixed with cold water to a final volume
of 300 ml. Liquid chocolate syrup was
added, and the mixture was served chilled
to limit the unpleasant taste of some of
the amino acids. Participants were kept on
a 24-h low-tryptophan diet (160 mg/day)
prior to both sessions. During the depletion
sessions, water, (de)caffeinated coffee, (herb)
tea, orange juice and protein-poor (50.05 g)
biscuits were allowed in standard amounts.
Patients had a low-tryptophan lunch 3 h
after drinking the mixture.
Assessments
We used the Comprehensive Psychopatho-
logical Rating Scale (CPRS) to assess symp-
toms (Goekoop et al, 1992). The CPRS is a
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68-item interview/observation scale with
item scores ranging from 0 (absent) to 6
(very severe), including the Montgomery–
Asberg Depression Rating Scale (MADRS;˚
Montgomery & Asberg, 1979) and the˚
Brief Anxiety Scale (Tyrer et al, 1984). Fac-
tor analytic research has revealed that the
CPRS consists of six factors (Goekoop et
al, 1992). Emotional dysregulation refers
to a number of symptoms common to both
anxiety and depression. Motivational inhi-
bition refers to dysregulation of appetite,
interest and motor inhibition, whereas
motor disinhibition refers to ‘manic-like’
symptoms. The subscale behavioural disin-
tegration refers to items such as agitation,
slowness of movement and emotional indif-
ference. Perceptual disintegration refers to
psychotic symptoms. Autonomic dysregula-
tion measures autonomic arousal/anxiety.
For the present study, a number of ques-
tions were added to the CPRS interview,
to allow scoring of the 17-item HRSD.
Ratings were performed by a trained inter-
viewer who was masked to the sequence of
the mixtures and to the research question
(i.e. the specificity question).
Self-report measures included the Beck
Depression Inventory II (BDI–II; Beck et
al, 1996) and the Positive and Negative
Affect Schedule (PANAS; Watson et al,
1988). The BDI–II is more focused on cog-
nitions than other depression scales, and
has three subscales: affective, somatic, cog-
nitive (Van der Does, 2002). The PANAS is
based on the tripartite model of anxiety and
depression (Watson et al, 1988). It mea-
sures negative affect (common to anxiety/
distress and depression) and positive affect
(low scores specific for depression). Partici-
pants also rated a list of 48 physical symp-
toms on a five-point scale.
The Self-referent Adjectives Encoding
and Recall Task (SAERT; Dobson & Shaw,
1987) was used to assess self-schemata rele-
vant to depression. The task consists of a
random presentation of ten positive and
ten negative adjectives and six neutral
words, preceded by three neutral practice
trials. Words were selected from a validated
list of personality trait words (Anderson,
1968) and matched on word frequency,
word length and number of syllables. Each
word was presented twice. At the first pre-
sentation, participants had to decide as
quickly as possible whether or not the word
was self-descriptive. Immediately there-
after, the same word was presented again,
accompanied by a six-point scale ranging
from 73 (not at all applicable) to +3
(very applicable). Response speed was
emphasised for the initial (yes/no) ratings,
not for the second presentation. Immedi-
ately after the second presentation, partici-
pants were asked to recall the adjectives
presented.
Ethics questionnaire
The questionnaire contained 28 items con-
cerning the quality of the informed consent
procedure and participants’ experiences
during the study. Reasons for participation
were also collected. The questionnaire was
completed anonymously; a code could link
the questionnaire data to the project in
which the individual had participated.
The psychometric properties of the
questionnaire are unknown.
Blood plasma
We collected venous blood (10 ml) into
tubes containing ethylenediamine tetra-
acetic acid (EDTA) to determine the total
plasma tryptophan concentration and the
ratio of total tryptophan to large neutral
amino acids. Immediately after sampling,
plasma was centrifuged for 20 min at
2650 g and frozen at 765 8C prior to
quantitative amino acid analysis by high-
performance liquid chromatography
(Fekkes et al, 1995).
Procedure
After receiving oral and written infor-
mation about the study, eligible partici-
pants were invited to a screening
interview that included the SCID–IV, the
HRSD and MADRS questionnaires and an
interview with a dietician. During day 1
of each session, participants consumed the
prepacked low-tryptophan meals. Partici-
pants arrived at the laboratory the next
morning (8 or 9 a.m.) after an overnight
fast. Symptoms and side-effects were
assessed at baseline (arrival at the labora-
tory) (71 h), +6.5 h and the next morning
(+24 h). The SAERT was conducted at both
sessions at +4.5 h. Blood samples were
taken at 71 h, at +6 h and at +24 h. All
participants were tested individually and
were paid e115 for participation.
At the end of their participation, indi-
viduals were asked to complete the ethics
questionnaire and to mail it in a prepaid
envelope to an independent investigator.
The address was a university in a different
city, and it was emphasised that the data
would remain confidential. To test whether
the questions were well understood, we
administered the questionnaire in a semi-
structured interview format to the first four
participants. The results did not differ from
the other completed questionnaires. The
study was approved by an independent
medical ethics committee.
Statistical analysis
All variables were examined for accuracy of
data entry, missing values and fit between
their distributions and the assumptions of
data analysis. To analyse the mood ratings,
we used general linear models (GLM) for
repeated measures with intervention
(100 g amino acids v. 25 g amino acids)
and time of assessment (pre- v. post-
depletion v. the next day) as within-subject
factors and gender as a between-subject
factor. Contrasts tested for differences
between specific time points.
Although the choice of the scales was
based on prior research and theoretical con-
siderations, a more stringent level of a may
be needed to keep overall a under control.
This could cause a power problem,
although the sample size of our study is
comparable with those of other acute
tryptophan depletion studies. To correct
for multiple comparisons and to retain
reasonable power, we set a at 0.15
(Stevens, 1996). Because there were 14
sub-scales, each variable was tested at
the 0.15/14¼0.01 level of significance.
Contrast tests were not corrected because
they were planned.
For each significant scale, effect size
(Cohen’s d) was calculated as follows
(Cortina & Nouri, 2000; Rosnow &
Rosenthal, 2003):
Cohen’s d¼M1–M2/spooled
where spooled¼H[(s12+s22)/2]; M1 and M2
are the means of each scale at baseline
and at time t¼+6.5 h; and s12 and s22 are
the corresponding variances.
For the SAERT, intervention was the
only within-subject factor. Clinical and
demographic variables were analysed by
univariate GLM and w2-tests.
RESULTS
Demographic data
Of 23 individuals who satisfied the inclu-
sion criteria, 21 completed the study. Two
(both male) withdrew after the first session;
the first owing to a severe headache on the
depletion day (after 25 g amino acids), the
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second because of health problems after the
first session (100 g amino acids) unlikely to
be caused by acute tryptophan depletion.
These two are not included in the analyses.
One female participant vomited about
10 min after ingestion of the 100 g mixture,
but she was able to complete both sessions.
Because the reduction of plasma trypto-
phan levels with the 100 g mixture in this
participant was only marginally higher than
with the 25 g mixture (64% v. 55%), and
much lower than the average reduction
with the 100 g mixture (see below), this
individual was also excluded.
Data screening
One participant missed one item on the
PANAS positive scale; this item score was
replaced by the mean of the remaining
items for that individual on that scale.
Using Mahalonobis distances and the
standardised residuals criterion, we de-
tected an outlier on the MADRS and CPRS
sub-scales of emotional dysregulation
and motivational inhibition (d2416.1;
| z-residual |43) and HRSD (d2¼15.3;
| z-residual |43) and HRSD (d2¼15.3;
| z-residual |43). This patient had a
response with the 25 g mixture and no
response after 100 g. The clinical and
demographic characteristics of the sample
are presented in Table 1.
Biochemical effects
Full depletion significantly reduced total
tryptophan and the tryptophan/large
neutral amino acids ratio at +6 h by 86%
(s.d.¼5.5) and 93% (s.d.¼4.2), respec-
tively. During partial depletion, the average
reductions were 47% (s.d.¼14.3) for total
tryptophan and 42% (s.d.¼17.1) for the
tryptophan/large neutral amino acids ratio.
Symptoms
The behavioural effects of both the 25 g and
100 g mixtures are presented in Table 2.
Significant time6intervention effects were
found for the HRSD (F¼8.5, d.f.¼2,34,
P¼0.001), the MADRS (F¼10.6, d.f.¼
2,34, P50.001), and the CPRS sub-scales
of emotional dysregulation (F¼6.7,
d.f.¼2,34, P¼0.003), motivational inhibi-
tion (F¼7.8, d.f.¼2,34, P¼0.002) and
behavioural disintegration (F¼5.4,
d.f.¼2,36, P¼0.009). The MADRS change
score data revealed two clearly separable
groups 7 participants had a mood change
of at least six points (range 6–12) and the
remaining 13 participants had no mood
change (range 71 to +2). The HRSD gave
a comparable division, but less clearly se-
parable groups: 7 participants had a change
of at least three points (range 3–6), the
remaining participants had smaller or no
changes (range 72 to +2). The agreement
between the two scales was 90% (kappa
0.56, P¼0.01). The interaction for the
BDI–cognitive sub-scale approached sig-
nificance (F¼3.3, d.f.¼2,36, P¼0.05) and
the BDI–total was significant (F¼3.9,
d.f.¼2,36, P¼0.03).
The total number of side-effects
decreased in both sessions. Scores that were
notably lower at t¼+6.5 h compared with
t¼71 h were ‘angry/irritable’, ‘sweating’
and ‘tension’. Scores on the items ‘nausea’
and ‘feel sick’ increased, with no differences
between conditions.
Self-referent Adjectives Encoding
and Recall Task (SAERT)
Prior to analysis, consistency of the answers
across presentations was checked. Inconsis-
tent answers (e.g. if a participant pressed
the ‘yes’ button for the word ‘lazy’ and then
rated it as ‘not applicable’ on second rating)
were analysed separately. Outcome mea-
sures were highly skewed, except for per-
centage of words recalled. Reaction times
were log10 transformed. Non-parametric
tests were used for the other skewed vari-
ables of the SAERT because transforma-
tions were unsuccessful.
Participants were more likely to rate
positive than negative traits as self-
descriptive, and they needed less time for
positive than for negative traits to decide
whether they were self-descriptive. There
was no main effect of acute tryptophan
depletion. However, in responders (D
MADRS 56) full depletion tended to
decrease the consistency of positive trait
ratings compared with partial depletion
(mean % consistency 90% (s.d.¼1.1) v.
96% (s.d.¼0.8); Z¼71.89, P¼0.06, two-
tailed; Fisher exact P¼0.04, one-tailed).
This was not true for non-responders
(mean % consistency 88% (s.d.¼1.0) v.
92% (s.d.¼1.0)). Participants who were
inconsistent usually first pressed the ‘yes’
button (under time pressure) and then
rated it as ‘not applicable’ (full deple-
tion: 17 times; partial depletion: 18 times);
the reverse happened only once under both
conditions.
There were significant effects of in-
tervention (F¼4.7, d.f.¼1,18, P¼0.04)
and intervention6mood response (F¼5.7,
d.f.¼1,18, P¼0.03) on memory for positive
words. Full depletion decreased immediate
recall of positive words in responders but
not in non-responders (38% v. 2% relative
to partial depletion). There were no other
differences between responders and non-
responders.
Computation of effect sizes
Cohen’s d for the significant symptom
scales are displayed in Table 3.
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SSRI, selective serotonin reuptake inhibitor; SNRI,
serotonin^noradrenaline reuptake inhibitor.
1. Higher vocational education, university.
2. Secondary education at intermediate and higher
level; senior secondary vocational education.
3. Primary education, lower-level secondary education.
4. Paroxetine (n¼5); fluoxetine (n¼2); citalopram
(n¼2); fluvoxamine (n¼2); sertraline (n¼2).
5. Venlafaxine (75^225mg) (n¼5); nefazodone
hydrochloride (150mg) (n¼2).
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Gender effects
At baseline, there were no significant demo-
graphic or clinical differences between
males and females (Fig. 1). Morning
(t¼71 h) MADRS scores were higher in
females at both sessions (partial depletion
F¼4.3, d.f.¼1,17, P¼0.05; full depletion
F¼6.9, d.f.¼1,17, P¼0.02) and the
intervention6time6gender interaction
was significant (F¼6.9, d.f.¼2,34,
P¼0.003).
The increase of MADRS scores between
t¼71 h and t¼+6.5 h after full depletion
was larger in females (Fig. 1). All
responders were women. Females also
tended to have a larger increase of BDI–
somatic scores than males in the full
depletion condition at t¼+6.5 h (P¼0.07).
Order of administration
Type of intervention did not interact with
order of administration; neither were there
any higher-order interaction effects. On
the SAERT, participants needed less time
to decide whether a word was self-
descriptive during the second session, irres-
pective of intervention or word valence
(F¼23.3, d.f.¼1,18, P50.001).
Questionnaire about ethical
aspects of the acute tryptophan
depletion
Of the 41 questionnaires, 36 were returned
(20 participants of the present study, 16
from the other depletion project). Two
questionnaires (1 present study, 1 other
project) were identified as completed by
individuals who withdrew from the trials
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Table 2 Mood assessment scores according to intervention and time of assessment, t
Assessment instrument Intervention
Partial acute tryptophan depletion (25 gmixture) Full acute tryptophan depletion (100gmixture)
t¼71h t¼+6.5h t¼+24h t ¼71h t¼+6.5h t¼+24h
Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d.
CPRS
Emotional dysregulation 6.8 6.2 6.6 6.6 6.2 6.1 7.9 5.9 11.9* 11.7 5.7{ 7.1
Motivational inhibition 0.9 1.3 0.7 1.3 0.9 1.5 1.3 1.3 2.7* 3.2 0.9{ 1.5
Motivational dysinhibition 0.2 0.4 0.2 0.7 0.1 0.4 0.2 0.9 0.4 0.7 0.2 0.4
Perceptual disintegration 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.5 0.0 0.2
Behavioural disintegration 0.3 0.6 0.4 0.7 0.5 0.7 0.5 1.0 1.2* 1.4 0.2{ 0.6
Autonomic dysregulation 1.5 1.5 1.4 1.8 1.2 1.2 1.3 1.4 2.0 2.4 1.5 2.5
MADRS 3.7 3.9 3.7 3.8 3.6 3.9 4.6 3.9 7.9* 7.8 3.4{ 4.4
BAS 2.0 1.8 2.0 3.0 1.9 2.3 2.7 2.8 3.5 4.8 2.0{ 3.5
HRSD 2.4 1.7 2.2 1.9 2.9 2.1 2.9 2.1 4.4* 3.0 2.5{ 2.7
BDI
Affective 1.4 1.7 1.3 1.7 1.3 1.8 1.9 2.4 1.8 2.3 1.4 1.9
Cognitive 2.6 3.1 2.3 3.4 1.8 2.8 2.2 3.1 2.6* 3.4 1.2{ 2.3
Somatic 3.6 3.1 3.5 3.2 3.0 3.2 3.4 2.6 3.8 3.5 2.3{ 2.7
Total score 7.7 7.5 7.2 8.0 6.1 7.4 7.6 7.1 8.2 8.6 4.9{ 5.6
PANAS
Positive 27.9 7.6 27.4 9.5 28.0 9.6 27.9 9.0 24.91 10.3 27.9{ 9.5
Negative 14.5 5.8 13.0 4.9 13.0 3.7 14.2 5.1 13.6 4.2 12.7 3.5
Side-effects 9.5 6.5 6.8 6.0 6.1 5.5 7.4 6.6 6.3 6.3 4.7 4.9
Univariate contrast tests: *P50.05 v. t¼71h; { P50.05 v. t¼+6.5 h.
CPRS,Comprehensive Psychopathological Rating Scale; MADRS,Montgomery^—sberg Depression Rating Scale; BAS, Brief Anxiety Scale; HRSD,Hamilton Rating Scale for
Depression; BDI, Beck Depression Inventory; PANAS, Positive and Negative Affectivity Scale.
1. P¼0.07 v. t¼71h.
Table 3 Confidence intervals and effect sizes of the significantmood assessment scores.Values are calculated
for the full depletion condition; t¼+6.5 minus t¼71.Negative dmeans worsening of symptoms
Assessment instrument 95% confidence limit d
Lower Upper
MADRS 75.40 71.23 70.54
HRSD 72.64 70.31 70.58
CPRS emotional dysregulation 77.31 70.68 70.43
CPRSmotivational inhibition 72.64 70.20 70.57
CPRS behavioural disintegration 71.18 70.12 70.57
BDI cognitive 70.86 0.16 70.12
MADRS,Montgomery^—sberg Depression Rating Scale; HRSD,Hamilton Rating Scale for Depression; CPRS,
Comprehensive Psychopathological Rating Scale; BDI, Beck Depression Inventory.
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by the content of the answers to open-
ended questions.
The main results are summarised
in Table 4. All participants were quite
satisfied with the informed consent pro-
cedure and reported that they had felt con-
fident to decide whether to participate.
More than half reported that participation
in the study had changed their perception
of their illness. Changes that were men-
tioned included that the study had helped
them to gain more insight and facilitated
acceptance of being vulnerable. Some
participants mentioned that the transient
return of symptoms had made them realise
how much they had improved during treat-
ment. Two participants interpreted their
experiences as evidence for a biological
cause of their depression, and felt less
responsible. All changes were perceived as
positive.
The informed consent procedure had
been very well understood. In response to
a question about whether the participant
expected to get better treatment after parti-
cipation, 90% (n¼32) answered ‘not at all’
and 11% (n¼4) ‘slightly’. Regarding moti-
vation to participate (open-ended ques-
tion), 58% (n¼21) wanted to contribute
to the development of better treatments in
the future. Others participated because of
gratefulness towards the hospital or general
interest in science. Two participants also
mentioned financial reasons.
There were no significant differences
between the two projects on any of the
items investigated. The evaluation of the
identified withdrawals was not different
from the other participants. One who with-
drew (a female mood responder) had felt
unprepared for how big the effect would
be, but she still reported that the study
had been helpful, in the sense that it had
convinced her that she is less responsible
for her depression than she had thought.
DISCUSSION
Could the depletion procedure
be explained well to participants?
Symptom provocation studies have become
controversial, particularly in the USA.
Questions have been raised concerning the
risk/benefit ratio for participants, their
capacity to decide whether to participate
and the provision of adequate informed
consent (Miller & Rosenstein, 1997;
Michels, 1999). This is the first acute tryp-
tophan depletion study to systematically
collect the views of participants. Individ-
uals did not regret participating, and they
had understood the informed consent pro-
cedure. Despite the provocation of symp-
toms and the fact that there was no direct
benefit, some participants still experienced
personal advantages. Two interpreted their
experiences as evidence of a biological basis
for their depression and felt less responsible
for their illness. The influence of this on the
future course of illness should be further
investigated, as well as the generalisability
to other symptom provocation studies. To
justify future challenge studies, it may be
useful to routinely investigate participants’
subjective experiences in this type of
research.
Is the acute tryptophan depletion
response a specific model
of depressive relapse?
Full acute tryptophan depletion signifi-
cantly increased depressive symptoms as
measured by the MADRS and HRSD. The
MADRS increase was larger in females
than in males. The menstrual cycle was
not taken into account in the present study,
but the finding is consistent with our
pooled reanalysis of previous acute
tryptophan depletion studies (Booij et al,
2002).
Almost all acute tryptophan depletion
studies in individuals with remitted depres-
sion have relied exclusively on the HRSD,
and no previous study has measured a
broad range of symptoms. However, some
studies added self-report questionnaires
such as the Profile of Mood States, or pro-
vided qualitative descriptions of the ‘re-
lapse’ (Smith et al, 1997; Lam & Yatham,
2003). Full but not partial depletion
affected the CPRS sub-scales emotional
dysregulation, motivational inhibition and
behavioural disintegration. No significant
effects were found on the sub-scales moti-
vational disinhibition (elation, pressure of
speech, ‘manic-like’ symptoms), perceptual
disintegration (psychotic symptoms), auto-
nomic dysregulation (autonomic arousal/
anxiety), or on the Brief Anxiety Scale.
Similarly, depletion did not change PANAS
negative affect (common to anxiety and
stress) but tended to decrease positive affect
(indicative of depression). The lack of effect
on anxiety is of interest, since different
serotonergic projections and receptors
may mediate both depression and anxiety
(Graeff et al, 1996).
It is noteworthy that the behavioural
changes following acute tryptophan
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Fig.1 The effects of acute tryptophandepletion on
the Montgomery^—sberg Depression Rating Scale
(MADRS) according to gender; ---*--- females, full
depletion; ---&--- males, full depletion; ---~--- females,
partial depletion; ---̂ --- males, partial depletion.
*F¼5.1, d.f.¼1,17, P¼0.04.
Table 4 Most relevant items of the ethics questionnaire
Item Mean (s.d.)
How do you rate the information received about:
the aim of the study? (1¼very bad, 4¼very good) 3.4 (0.6)
the tests and procedures? (1¼very bad, 4¼very good) 3.4 (0.5)
the possible effects of the amino acidmixture? (1¼very bad, 4¼very good) 3.0 (0.8)
In retrospect, do you think that you had all the information to decide whether
or not to participate? (1¼no, not at all, 4¼yes, completely)
3.4 (0.5)
Did the studymeet your expectations? (1¼no, not at all, 4¼yes, very well) 3.0 (0.7)
Has your perception of your (previous) depression changed? (1¼not at all,
4¼verymuch)
2.0 (1.0)
Did you expect to receive better treatment because you participated in this study?
(1¼not at all, 4¼verymuch)
1.1 (0.3)
Evaluation of financial compensation (1¼high, 2¼adequate, 3¼low) 2.0 (0.5)
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depletion were larger on observer-rating
scales than on self-report questionnaires,
the latter often resulting in trends or non-
significant results. However, these changes
were also consistent with a specific depres-
sive response (increase of BDI–total and
BDI–cognitive, decrease of positive affect).
As noted previously (Booij et al, 2003),
people with depression may use standards
other than those used by healthy controls
to rate changes in mood over a short time
interval. This is supported by the finding
on the SAERT; responders more often
rated positive traits as self-descriptive
but rated these as ‘not applicable’ on reflec-
tion. The same effect may occur with self-
rating scales, where individuals are typi-
cally instructed to choose the first answer
that appears right.
Does acute tryptophan depletion
change depression-related
self-schemata?
Although acute tryptophan depletion sig-
nificantly increased depression-related cog-
nitions (indicated by BDI–cognitive), full
depletion did not affect self-schemata.
Acute tryptophan depletion negatively in-
fluenced the recall of positive traits, but
only in responders. A number of studies
have demonstrated that people with depres-
sion are impaired in the recall of positive in-
formation, and that they are more likely to
store and recall information which is con-
gruent with their mood state (Burt et al,
1995). The present study suggests that this
mood-congruent memory bias is mediated
by low serotonin.
Are the statistically significant
changes in mood also clinically
significant?
Although statistically significant, the in-
creases in HRSD and MADRS ratings were
relatively low. However, effect sizes were
around 0.50, which is clinically relevant
(Cohen, 1988).
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